» Articles » PMID: 37721282

Interplay Between Mesenchymal Stromal Cells and the Immune System After Transplantation: Implications for Advanced Cell Therapy in the Retina

Overview
Date 2023 Sep 18
PMID 37721282
Authors
Affiliations
Soon will be listed here.
Abstract

Advanced mesenchymal stromal cell-based therapies for neurodegenerative diseases are widely investigated in preclinical models. Mesenchymal stromal cells are well positioned as therapeutics because they address the underlying mechanisms of neurodegeneration, namely trophic factor deprivation and neuroinflammation. Most studies have focused on the beneficial effects of mesenchymal stromal cell transplantation on neuronal survival or functional improvement. However, little attention has been paid to the interaction between mesenchymal stromal cells and the host immune system due to the immunomodulatory properties of mesenchymal stromal cells and the long-held belief of the immunoprivileged status of the central nervous system. Here, we review the crosstalk between mesenchymal stromal cells and the immune system in general and in the context of the central nervous system, focusing on recent work in the retina and the importance of the type of transplantation.

Citing Articles

Differential response of injured and healthy retinas to syngeneic and allogeneic transplantation of a clonal cell line of immortalized olfactory ensheathing glia: a double-edged sword.

Norte-Munoz M, Portela-Lomba M, Sobrado-Calvo P, Simon D, Di Pierdomenico J, Gallego-Ortega A Neural Regen Res. 2024; 20(8):2395-2407.

PMID: 39359096 PMC: 11759016. DOI: 10.4103/NRR.NRR-D-23-01631.


Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management.

Zhang J, Wu P, Wen Q Stem Cell Res Ther. 2024; 15(1):211.

PMID: 39020426 PMC: 11256674. DOI: 10.1186/s13287-024-03828-8.

References
1.
Magatti M, Masserdotti A, Signoroni P, Vertua E, Stefani F, Silini A . B Lymphocytes as Targets of the Immunomodulatory Properties of Human Amniotic Mesenchymal Stromal Cells. Front Immunol. 2020; 11:1156. PMC: 7295987. DOI: 10.3389/fimmu.2020.01156. View

2.
Andrzejewska A, Dabrowska S, Lukomska B, Janowski M . Mesenchymal Stem Cells for Neurological Disorders. Adv Sci (Weinh). 2021; 8(7):2002944. PMC: 8024997. DOI: 10.1002/advs.202002944. View

3.
Plock J, Schnider J, Schweizer R, Zhang W, Tsuji W, Waldner M . The Influence of Timing and Frequency of Adipose-Derived Mesenchymal Stem Cell Therapy on Immunomodulation Outcomes After Vascularized Composite Allotransplantation. Transplantation. 2016; 101(1):e1-e11. DOI: 10.1097/TP.0000000000001498. View

4.
Reisenhofer M, Balmer J, Enzmann V . What Can Pharmacological Models of Retinal Degeneration Tell Us?. Curr Mol Med. 2017; 17(2):100-107. DOI: 10.2174/1566524017666170331162048. View

5.
Melief S, Schrama E, Brugman M, Tiemessen M, Hoogduijn M, Fibbe W . Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells. 2013; 31(9):1980-91. DOI: 10.1002/stem.1432. View